In CRC, CXCR4 is upregulated in chemoresistant tumor cells, and lymph node–derived stromal cells enhance resistance to oxaliplatin and 5‐FU via an SDF1/CXCR4 dependent manner.272. The gene discussed is CXCL12; the disease is neoplasm.